Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

[1]  H. Friedman,et al.  Bevacizumab and daily temozolomide for recurrent glioblastoma , 2012, Cancer.

[2]  R. Beroukhim,et al.  Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure , 2011, Journal of Neuro-Oncology.

[3]  R. McLendon,et al.  Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy , 2011, Journal of Neuro-Oncology.

[4]  R. McLendon,et al.  Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. , 2010, Neuro-oncology.

[5]  Helen X. Chen,et al.  Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Grothey,et al.  Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). , 2010 .

[7]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[9]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Olson,et al.  Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma , 2010, Journal of Neuro-Oncology.

[11]  T. Mikkelsen,et al.  The role of salvage reirradiation for malignant gliomas that progress on bevacizumab , 2010, Journal of Neuro-Oncology.

[12]  R. McLendon,et al.  Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study , 2009, British Journal of Cancer.

[13]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[14]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Wen,et al.  Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. , 2009, Neuro-oncology.

[16]  R. Jain,et al.  Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Mikkelsen,et al.  Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis , 2009, Journal of Neuro-Oncology.

[20]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[21]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Tracy T Batchelor,et al.  Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. , 2007, Neuro-oncology.

[24]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  R. McLendon,et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.